FDA authorized a reduced-risk claim for 20 ZYN nicotine pouches for adults who switch completely from cigarettes.
The US Food and Drug Administration (FDA) has issued modified risk tobacco product (MRTP) orders for 20 ZYN nicotine pouch products, authorizing a reduced-risk marketing claim for adults who switch completely from cigarettes to the oral nicotine pouches. The orders make ZYN the first nicotine pouch product category to receive MRTP authorization, according to Philip Morris International (PMI), which announced the decision June 30.¹
“FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” Stacey Kennedy, chief executive officer of PMI U.S., said in the announcement. Kennedy said the authorization permits communication of “FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease and lung cancer.”¹
The authorized claim states: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.”¹ The decision is regulatory rather than therapeutic: ZYN remains a tobacco product, not an FDA-approved smoking cessation medication. For clinicians, the order may be relevant in counseling adult patients who smoke and are unwilling or unable to quit nicotine use, but it does not change guideline-supported first-line approaches to tobacco cessation.
The MRTP pathway allows FDA to authorize marketing of a tobacco product with modified risk information when the agency determines the product, as actually used by consumers, will significantly reduce harm and the risk of tobacco-related disease to individual users and benefit population health, including people who do not currently use tobacco products.² According to the PMI announcement, FDA concluded the ZYN applications satisfied section 911(g)(1)(A) and (B) requirements and authorized the reduced-risk information effective immediately.¹
The orders cover 20 ZYN variants across 10 flavors, each in 3-mg and 6-mg nicotine strengths: Cool Mint, Peppermint, Spearmint, Wintergreen, Citrus, Coffee, Cinnamon, Smooth, Chill, and Menthol.¹ ZYN pouches deliver nicotine through oral absorption and do not involve combustion or inhalation of smoke. PMI stated that FDA’s earlier premarket tobacco product application authorization for ZYN in January 2025 found substantially lower amounts of harmful constituents compared with cigarettes and most smokeless tobacco products, including moist snuff and snus.¹
The company also cited FDA-reviewed behavioral data indicating that some adults who smoked and began using ZYN reduced cigarette consumption over time. In the source announcement, more than half of surveyed adults reported no cigarette consumption in the prior 30 days after starting ZYN; among those who continued smoking, 80.7% reduced cigarette consumption and 57.2% reduced cigarettes per day by more than 50%.¹ The announcement did not provide full study design details, comparator groups, follow-up duration, or peer-reviewed publication data for those findings.
The clinical context remains complex. Cigarette smoking is causally linked to cancer, cardiovascular disease, chronic obstructive pulmonary disease, stroke, and multiple other conditions, and remains a leading preventable cause of morbidity and mortality in the United States.³ Complete cessation of combustible tobacco remains the optimal clinical goal. The US Preventive Services Task Force recommends that clinicians ask all adults about tobacco use, advise them to stop, and provide behavioral interventions and FDA-approved pharmacotherapy for cessation when appropriate.⁴
Nicotine pouches occupy a harm-reduction category distinct from approved cessation medications such as nicotine replacement therapy, varenicline, and bupropion. The MRTP authorization permits a comparative risk claim versus cigarettes; it should not be interpreted as evidence that nicotine pouches are risk-free, appropriate for people who do not use tobacco, or established as cessation treatments. Nicotine dependence, youth uptake, dual use with cigarettes, and long-term oral and cardiovascular safety remain important surveillance issues.
The key interpretive question for clinicians is whether authorized risk communication helps adults who smoke transition away from combustible tobacco without expanding nicotine initiation or sustained dual use. FDA’s MRTP standard incorporates both individual risk reduction and population-level effects, but real-world impact will depend on product marketing, uptake patterns, complete switching rates, and postmarket monitoring. The source announcement did not describe any new randomized trial outcomes or long-term clinical endpoint data.
For now, the decision adds a regulatory signal that FDA considers the authorized ZYN products lower risk than cigarettes when used instead of smoking. In practice, clinicians may need to distinguish this from cessation counseling: adult patients who smoke should still be offered evidence-based quitting support, while patients already using nicotine pouches should be counseled that avoiding cigarettes is beneficial but ongoing nicotine dependence is not medically neutral.
